Novartis Teams Up With CureVac To Make COVID-19 Vaccine

Joins Bayer As A Production Partner

The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.

Business teamwork puzzle pieces.
Novartis a good fit to solve CureVac's manufacturing needs • Source: Archive

With Bayer AG already lending a helping hand, CureVac NV has enlisted another pharma giant in Novartis AG to assist with the production of its investigational mRNA COVID-19 vaccine.

The Swiss major has agreed to manufacture the mRNA and bulk drug product for CureVac's vaccine candidate CVnCoV, noting that "preparations for the start of production, technology transfer and test runs are already underway

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Trump’s MFN Executive Order More Rhetoric Than Action

 

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.